Search

Your search keyword '"Zlotta, Alexandre"' showing total 1,765 results
Start Over Author "Zlotta, Alexandre"
1,765 results on '"Zlotta, Alexandre"'

2. Second TURB, restaging TURB or repeat TURB in primary T1 non-muscle invasive bladder cancer: impact on prognosis?

Author

Beijert, Irene J., Hentschel, Anouk E., Bründl, Johannes, Compérat, Eva M., Plass, Karin, Rodríguez, Oscar, Subiela Henríquez, Jose D., Hernández, Virginia, de la Peña, Enrique, Alemany, Isabel, Turturica, Diana, Pisano, Francesca, Soria, Francesco, Čapoun, Otakar, Bauerová, Lenka, Pešl, Michael, Bruins, H. Maxim, Runneboom, Willemien, Herdegen, Sonja, Breyer, Johannes, Brisuda, Antonin, Calatrava, Ana, Rubio-Briones, José, Seles, Maximilian, Mannweiler, Sebastian, Bosschieter, Judith, Kusuma, Venkata R. M., Ashabere, David, Huebner, Nicolai, Cotte, Juliette, Contieri, Roberto, Mertens, Laura S., Claps, Francesco, Masson-Lecomte, Alexandra, Liedberg, Fredrik, Cohen, Daniel, Lunelli, Luca, Cussenot, Olivier, El Sheikh, Soha, Volanis, Dimitrios, Côté, Jean-François, Rouprêt, Morgan, Haitel, Andrea, Shariat, Shahrokh F., Mostafid, A. Hugh, Nieuwenhuijzen, Jakko A., Zigeuner, Richard, Dominguez-Escrig, Jose L., Hacek, Jaromir, Zlotta, Alexandre R., Burger, Maximilian, Evert, Matthias, Hulsbergen-van de Kaa, Christina A., van der Heijden, Antoine G., Kiemeney, Lambertus A. L. M., Soukup, Viktor, Molinaro, Luca, Gontero, Paolo, Llorente, Carlos, Algaba, Ferran, Palou, Joan, N’Dow, James, Ribal, Maria J., van der Kwast, Theo H., Babjuk, Marko, Sylvester, Richard J., and van Rhijn, Bas W. G.

Published
2024
Full Text
View/download PDF

5. Somatic driver mutation prevalence in 1844 prostate cancers identifies ZNRF3 loss as a predictor of metastatic relapse

Author

Fraser, Michael, Livingstone, Julie, Wrana, Jeffrey L, Finelli, Antonio, He, Housheng Hansen, van der Kwast, Theodorus, Zlotta, Alexandre R, Bristow, Robert G, and Boutros, Paul C

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Prostate Cancer, Cancer, Genetics, Human Genome, Urologic Diseases, 2.1 Biological and endogenous factors, 4.1 Discovery and preclinical testing of markers and technologies, Detection, screening and diagnosis, Aetiology, Biomarkers, Tumor, Cell Cycle, Cell Cycle Proteins, Gene Expression Regulation, Neoplastic, Humans, Male, Mutation, Neoplasm Recurrence, Local, Prevalence, Prognosis, Prostatic Neoplasms, Ubiquitin-Protein Ligases
Abstract

Driver gene mutations that are more prevalent in metastatic, castration-resistant prostate cancer (mCRPC) than localized disease represent candidate prognostic biomarkers. We analyze 1,844 localized (1,289) or mCRPC (555) tumors and quantify the prevalence of 113 somatic driver single nucleotide variants (SNVs), copy number aberrations (CNAs), and structural variants (SVs) in each state. One-third are significantly more prevalent in mCRPC than expected while a quarter are less prevalent. Mutations in AR and its enhancer are more prevalent in mCRPC, as are those in TP53, MYC, ZNRF3 and PRKDC. ZNRF3 loss is associated with decreased ZNRF3 mRNA abundance, WNT, cell cycle & PRC1/2 activity, and genomic instability. ZNRF3 loss, RNA downregulation and hypermethylation are prognostic of metastasis and overall survival, independent of clinical and pathologic indices. These data demonstrate a strategy for identifying biomarkers of localized cancer aggression, with ZNRF3 loss as a predictor of metastasis in prostate cancer.

Published
2021

7. Development, multi-institutional external validation, and algorithmic audit of an artificial intelligence-based Side-specific Extra-Prostatic Extension Risk Assessment tool (SEPERA) for patients undergoing radical prostatectomy: a retrospective cohort study

Author

Kwong, Jethro C C, Khondker, Adree, Meng, Eric, Taylor, Nicholas, Kuk, Cynthia, Perlis, Nathan, Kulkarni, Girish S, Hamilton, Robert J, Fleshner, Neil E, Finelli, Antonio, van der Kwast, Theodorus H, Ali, Amna, Jamal, Munir, Papanikolaou, Frank, Short, Thomas, Srigley, John R, Colinet, Valentin, Peltier, Alexandre, Diamand, Romain, Lefebvre, Yolene, Mandoorah, Qusay, Sanchez-Salas, Rafael, Macek, Petr, Cathelineau, Xavier, Eklund, Martin, Johnson, Alistair E W, Feifer, Andrew, and Zlotta, Alexandre R

Published
2023
Full Text
View/download PDF

8. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis

Author

Zlotta, Alexandre R, Ballas, Leslie K, Niemierko, Andrzej, Lajkosz, Katherine, Kuk, Cynthia, Miranda, Gus, Drumm, Michael, Mari, Andrea, Thio, Ethan, Fleshner, Neil E, Kulkarni, Girish S, Jewett, Michael A S, Bristow, Robert G, Catton, Charles, Berlin, Alejandro, Sridhar, Srikala S, Schuckman, Anne, Feldman, Adam S, Wszolek, Matthew, Dahl, Douglas M, Lee, Richard J, Saylor, Philip J, Michaelson, M Dror, Miyamoto, David T, Zietman, Anthony, Shipley, William, Chung, Peter, Daneshmand, Siamak, and Efstathiou, Jason A

Published
2023
Full Text
View/download PDF

9. Prognosis of Primary Papillary Ta Grade 3 Bladder Cancer in the Non–muscle-invasive Spectrum

Author

Beijert, Irene J., Hentschel, Anouk E., Bründl, Johannes, Compérat, Eva M., Plass, Karin, Rodríguez, Oscar, Subiela Henríquez, Jose D., Hernández, Virginia, de la Peña, Enrique, Alemany, Isabel, Turturica, Diana, Pisano, Francesca, Soria, Francesco, Čapoun, Otakar, Bauerová, Lenka, Pešl, Michael, Bruins, H. Maxim, Runneboom, Willemien, Herdegen, Sonja, Breyer, Johannes, Brisuda, Antonin, Calatrava, Ana, Rubio-Briones, José, Seles, Maximilian, Mannweiler, Sebastian, Bosschieter, Judith, Kusuma, Venkata R.M., Ashabere, David, Huebner, Nicolai, Cotte, Juliette, Mertens, Laura S., Claps, Francesco, Masson-Lecomte, Alexandra, Liedberg, Fredrik, Cohen, Daniel, Lunelli, Luca, Cussenot, Olivier, El Sheikh, Soha, Volanis, Dimitrios, Côté, Jean-François, Rouprêt, Morgan, Haitel, Andrea, Shariat, Shahrokh F., Mostafid, A. Hugh, Nieuwenhuijzen, Jakko A., Zigeuner, Richard, Dominguez-Escrig, Jose L., Hacek, Jaromir, Zlotta, Alexandre R., Burger, Maximilian, Evert, Matthias, Hulsbergen-van de Kaa, Christina A., van der Heijden, Antoine G., Kiemeney, Lambertus A.L.M., Soukup, Viktor, Molinaro, Luca, Gontero, Paolo, Llorente, Carlos, Algaba, Ferran, Palou, Joan, N'Dow, James, Ribal, Maria J., van der Kwast, Theo H., Babjuk, Marko, Sylvester, Richard J., and van Rhijn, Bas.W.G.

Published
2023
Full Text
View/download PDF

10. Multi-Center Assessment of Lymph-Node Density and Nodal-Stage to Predict Disease-Specific Survival in Patients with Bladder Cancer Treated by Radical Cystectomy

Author

van Gennep, Erik J., primary, Claps, Francesco, additional, Bostrom, Peter J., additional, Shariat, Shahrokh F., additional, Neuzillet, Yann, additional, Zlotta, Alexandre R., additional, Trombetta, Carlo, additional, Eckstein, Markus, additional, Mertens, Laura S., additional, Bussani, Rossana, additional, Burger, Maximilian, additional, Boormans, Joost L., additional, Wullich, Bernd, additional, Hartmann, Arndt, additional, Mayr, Roman, additional, Pavan, Nicola, additional, Bartoletti, Riccardo, additional, Mir, M. Carmen, additional, Pouessel, Damien, additional, van der Hoeven, John, additional, van der Kwast, Theo H., additional, Allory, Yves, additional, Zuiverloon, Tahlita C.M., additional, Lotan, Yair, additional, and van Rhijn, Bas W.G., additional

Published
2024
Full Text
View/download PDF

11. PD38-10 STENTING VERSUS NEPHROSTOMY TUBES FOR BLADDER CANCER ASSOCIATED WITH HYDRONEPHROSIS: DOES STENTING INCREASE THE INCIDENCE OF UPPER TRACT UROTHELIAL CARCINOMA BY RETROGRADE TUMOR CELL SEEDING?

Author

Wettstein, Marian S., primary, Bernardino, Rui M., additional, Randhawa, Harkanwal, additional, Kwong, Jethro C. C., additional, Cheung, Douglas C., additional, Aminoltejari, Khatereh, additional, Fleshner, Neil E., additional, Zlotta, Alexandre R., additional, and Kulkarni, Girish S., additional

Published
2024
Full Text
View/download PDF

12. PD30-05 DEVELOPMENT AND EXTERNAL VALIDATION OF AN ARTIFICIAL INTELLIGENCE-BASED TOOL FOR PROGRESSION RISK ASSESSMENT IN NON-MUSCLE INVASIVE BLADDER CANCER (PROGRXN-BCA)

Author

Kwong, Jethro C. C., primary, Al-Daqqaq, Zizo, additional, Chelliahpillai, Yashan, additional, Lee, Soomin, additional, Kim, Kellie, additional, Ringa, Maximiliano, additional, Ali, Amna, additional, Feifer, Andrew, additional, Wettstein, Marian S., additional, Kassouf, Wassim, additional, Black, Peter C., additional, Breau, Rodney H., additional, Lodde, Michele, additional, Fairey, Adrian, additional, Lattouf, Jean-Baptiste, additional, Jeldres, Claudio, additional, Rendon, Ricardo, additional, Alimohamed, Nimira, additional, Chung, Peter, additional, Fleshner, Neil E., additional, Finelli, Antonio, additional, Zlotta, Alexandre R., additional, Johnson, Alistair E. W., additional, and Kulkarni, Girish S., additional

Published
2024
Full Text
View/download PDF

13. MP68-07 PROPORTION OF GLEASON 8-10 PROSTATE CANCER FOUND ON BIOPSY AND TUMOR AGGRESSIVENESS IN MATCHED COHORTS OF MEN IN ASIA AND WESTERN COUNTRIES

Author

Dong, Liang, primary, Lajkosz, Katherine, additional, Sanchez-Salas, Rafael, additional, Tiwari, Raj Vikesh, additional, Dias dos Santos, Caio Pasquali, additional, Dong, Baijun, additional, Pan, Jiahua, additional, Chan, Amy, additional, Woon, Dixon, additional, Kulkarni, Girish S., additional, Perlis, Nathan, additional, Hamilton, Rob, additional, Klotz, Laurence, additional, Wallis, Christopher J. D., additional, Macek, Petr, additional, Kae, Jack Tay, additional, Toi, Ants, additional, Finelli, Antonio, additional, Fleshner, Neil E., additional, Cathelineau, Xavier, additional, van der Kwast, Theodorus H., additional, Xue, Wei, additional, and Zlotta, Alexandre R., additional

Published
2024
Full Text
View/download PDF

14. PD19-04 IMPACT OF NOVEL PATIENT-CENTERED PATHOLOGY REPORTS ON MEN UNDERGOING PROSTATE BIOPSY: THE PAPR RANDOMIZED CONTROLLED TRIAL

Author

Kumar, Ravi M, primary, Lajkosz, Katherine, additional, Silberman, Amalia, additional, Finelli, Antonio, additional, Fleshner, Neil, additional, Hamilton, Robert, additional, Kulkarni, Girish, additional, Zlotta, Alexandre, additional, Berlin, Alejandro, additional, Papadakos, Janet, additional, Ghai, Sangeet, additional, Deniffel, Dominik, additional, Wiljer, David, additional, Alibhai, Shabbir, additional, Cafazzo, Joseph, additional, Haider, Masoom, additional, Lee, Odelia, additional, Calicchia, Lauren, additional, Janusonis, Isabella, additional, Lovas, Mike, additional, Kreidstein, Jayson, additional, Hiemstra, Jenna, additional, and Perlis, Nathan, additional

Published
2024
Full Text
View/download PDF

15. PD27-10 TEMPORAL VALIDATION OF AN ARTIFICIAL INTELLIGENCE TOOL (SEPERA) TO INFORM NERVE-SPARING STRATEGY DURING RADICAL PROSTATECTOMY AND COMPARISON AGAINST UROLOGISTS

Author

Pickel, Lauren, primary, Zhang, Kevin, additional, Booth, Ryan, additional, Shahid, Aiman, additional, Ringa, Maximiliano, additional, Ali, Amna, additional, Chan, Amy, additional, Perlis, Nathan, additional, Hamilton, Robert J., additional, Fleshner, Neil E., additional, Finelli, Antonio, additional, Johnson, Alistair E. W., additional, Kulkarni, Girish S., additional, Feifer, Andrew, additional, Zlotta, Alexandre R., additional, and Kwong, Jethro C. C., additional

Published
2024
Full Text
View/download PDF

16. Extended Results and Independent Validation of a Phase 2 Trial of Metastasis-Directed Therapy for Molecularly Defined Oligometastatic Prostate Cancer

Author

Glicksman, Rachel M., Ramotar, Matthew, Metser, Ur, Chung, Peter W., Liu, Zhihui, Vines, Douglass, Finelli, Antonio, Hamilton, Robert, Fleshner, Neil E., Perlis, Nathan, Zlotta, Alexandre R., Bayley, Andrew, Helou, Joelle, Raman, Srinivas, Kulkarni, Girish, Catton, Charles, Lam, Tony, Chan, Rosanna, Warde, Padraig, Gospodarowicz, Mary, Jaffray, David A., and Berlin, Alejandro

Published
2022
Full Text
View/download PDF

17. T1G1 Bladder Cancer: Prognosis for this Rare Pathological Diagnosis Within the Non–muscle-invasive Bladder Cancer Spectrum

Author

Beijert, Irene J., Hentschel, Anouk E., Bründl, Johannes, Compérat, Eva M., Plass, Karin, Rodríguez, Oscar, Subiela Henríquez, Jose D., Hernández, Virginia, de la Peña, Enrique, Alemany, Isabel, Turturica, Diana, Pisano, Francesca, Soria, Francesco, Čapoun, Otakar, Bauerová, Lenka, Pešl, Michael, Maxim Bruins, H., Runneboom, Willemien, Herdegen, Sonja, Breyer, Johannes, Brisuda, Antonin, Calatrava, Ana, Rubio-Briones, José, Seles, Maximilian, Mannweiler, Sebastian, Bosschieter, Judith, Kusuma, Venkata R.M., Ashabere, David, Huebner, Nicolai, Cotte, Juliette, Mertens, Laura S., Masson-Lecomte, Alexandra, Liedberg, Fredrik, Cohen, Daniel, Lunelli, Luca, Cussenot, Olivier, El Sheikh, Soha, Volanis, Dimitrios, Côté, Jean-François, Rouprêt, Morgan, Haitel, Andrea, Shariat, Shahrokh F., Mostafid, A. Hugh, Nieuwenhuijzen, Jakko A., Zigeuner, Richard, Dominguez-Escrig, Jose L., Hacek, Jaromir, Zlotta, Alexandre R., Burger, Maximilian, Evert, Matthias, Hulsbergen-van de Kaa, Christina A., van der Heijden, Antoine G., A.L.M. Kiemeney, Lambertus, Soukup, Viktor, Molinaro, Luca, Gontero, Paolo, Llorente, Carlos, Algaba, Ferran, Palou, Joan, N'Dow, James, Ribal, Maria J., van der Kwast, Theo H., Babjuk, Marko, Sylvester, Richard J., and van Rhijn, Bas.W.G.

Published
2022
Full Text
View/download PDF

18. Are there differences between de novo and secondary upper tract urothelial carcinoma tumours?

Author

Goldberg, Hanan, Cheung, Douglas C, Chandrasekar, Thenappan, Klaassen, Zachary, Wallis, Christopher JD, Kulkarni, Girish S, Sayyid, Rashid, Evans, Andrew, Masoomian, Mehdi, Bapat, Bharati, van der Kwast, Theodorus, Hamilton, Robert J, Zlotta, Alexandre, and Fleshner, Neil

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Patient Safety, Urologic Diseases, 2.1 Biological and endogenous factors, Aetiology, Good Health and Well Being, Clinical Sciences, Urology & Nephrology, Clinical sciences, Oncology and carcinogenesis
Abstract

IntroductionUpper tract urothelial carcinoma (UTUC) accounts for

Published
2019

19. A novel predictor of clinical progression in patients on active surveillance for prostate cancer

Author

Tan, Guan Hee, Finelli, Antonio, Ahmad, Ardalan, Wettstein, Marian S, Chandrasekar, Thenappan, Zlotta, Alexandre R, Fleshner, Neil E, Hamilton, Robert J, Kulkarni, Girish S, Ajib, Khaled, Nason, Gregory, and Perlis, Nathan

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Brain Disorders, Prevention, Cancer, Urologic Diseases, Aging, Clinical Research, Patient Safety, Prostate Cancer, 4.2 Evaluation of markers and technologies, Detection, screening and diagnosis, Urology & Nephrology, Clinical sciences, Oncology and carcinogenesis
Abstract

IntroductionActive surveillance (AS) is standard of care in low-risk prostate cancer (PCa). This study describes a novel total cancer location (TCLo) density metric and aims to determine its performance in predicting clinical progression (CP) and grade progression (GP).MethodsThis was a retrospective study of patients on AS after confirmatory biopsy (CBx). We excluded patients with Gleason ≥7 at CBx and 0.05) was independently associated with time to CP (hazard ratio [HR] 4.70; 95% confidence interval [CI] 2.62-8.42; p

Published
2019

24. Replacing surveillance cystoscopy with urinary biomarkers in followup of patients with non-muscle-invasive bladder cancer: Patients’ and urologic oncologists’ perspectives

Author

Sayyid, Rashid K, Sayyid, Abdallah K, Klaassen, Zachary, Hersey, Karen, Goldberg, Hanan, Perlis, Nathan, Ahmad, Ardalanejaz, Leao, Ricardo, Chandrasekar, Thenappan, Fadaak, Kamel, Madi, Rabii, Terris, Martha K, Finelli, Antonio, Hamilton, Robert J, Kulkarni, Girish S, Zlotta, Alexandre R, and Fleshner, Neil E

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Urologic Diseases, Cancer, Clinical Research, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, Clinical Sciences, Urology & Nephrology, Clinical sciences, Oncology and carcinogenesis
Abstract

INTRODUCTION:Urinary biomarkers are being developed to detect bladder cancer recurrence/progression in patients with non-muscle-invasive bladder cancer (NMIBC). We conducted a questionnaire-based study to determine what diagnostic accuracy and cost would such test(s) need for both patients and urologic oncologists to comfortably forgo surveillance cystoscopy in favour of these tests. METHODS:Surveys were administered to NMIBC patients at followup cystoscopy visit and to physician members of the Society of Urologic Oncology. Participants were questioned about acceptable false-negative (FN) rates and costs for such alternatives, in addition to demographics that could influence chosen error rates and costs. RESULTS:A total of 137 patient and 51 urologic oncologist responses were obtained. Seventy-seven percent of patients were not comfortable with urinary biomarker(s) alternatives to repeat cystoscopy, with a further 14% willing to accept such alternatives only if the FN rate were 0.5% or lower. Seventy-five percent of urologic oncologists were comfortable with an alternative urinary biomarker test(s), with 37% and 33% willing to accept FN rates of 5% and 1%, respectively. Forty-seven percent of patients were not willing to pay out-of-pocket for such tests, while 61% of urologic oncologists felt that a price range of $100-500 would be reasonable. CONCLUSIONS:This is the first survey evaluating patient and urologic oncologist perspectives on acceptable error rates and costs for urinary biomarker alternatives to surveillance cystoscopy for patients with NMIBC. Despite potential responder bias, this study suggests that urinary biomarker(s) will require sensitivity equivalent to that of cystoscopy in order to completely replace it in surveillance of patients with NMIBC.

Published
2018

25. MRI-guided Focused Ultrasound Focal Therapy for Intermediate-Risk Prostate Cancer: Final Results from a 2-year Phase II Clinical Trial

Author

Ghai, Sangeet, primary, Finelli, Antonio, additional, Corr, Kateri, additional, Lajkosz, Katherine, additional, McCluskey, Stuart, additional, Chan, Rosanna, additional, Gertner, Mark, additional, van der Kwast, Theodorus H., additional, Incze, Peter F., additional, Zlotta, Alexandre R., additional, Kucharczyk, Walter, additional, and Perlis, Nathan, additional

Published
2024
Full Text
View/download PDF

26. DEVELOPMENT AND EXTERNAL VALIDATION OF NIMBLE, AN ARTIFICIAL INTELLIGENCE-BASED TOOL TO PREDICT PROGRESSION IN NON-MUSCLE INVASIVE BLADDER CANCER: A RETROSPECTIVE MULTI-INSTITUTIONAL COHORT STUDY

Author

Kwong, Jethro C.C., primary, Al-Daqqaq, Zizo, additional, Chelliahpillai, Yashan, additional, Lee, Soomin, additional, Kim, Kellie, additional, Chan, Amy, additional, Kuk, Cynthia, additional, Zlotta, Alexandre R., additional, Ringa, Maximiliano, additional, Ali, Amna, additional, Feifer, Andrew, additional, Perlis, Nathan, additional, Lee, Jason Y., additional, Hamilton, Robert J., additional, Fleshner, Neil E., additional, Finelli, Antonio, additional, Kulkarni, Girish S., additional, and Johnson, Alistair E.W., additional

Published
2024
Full Text
View/download PDF

30. Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non–muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non–muscle-invasive Bladder Cancer Guidelines Panel Study

Author

van Rhijn, Bas W.G., Hentschel, Anouk E., Bründl, Johannes, Compérat, Eva M., Plass, Karin, Rodríguez, Oscar, Subiela Henríquez, Jose D., Hernández, Virginia, de la Peña, Enrique, Alemany, Isabel, Turturica, Diana, Pisano, Francesca, Soria, Francesco, Čapoun, Otakar, Bauerová, Lenka, Pešl, Michael, Bruins, H. Maxim, Runneboom, Willemien, Herdegen, Sonja, Breyer, Johannes, Brisuda, Antonin, Calatrava, Ana, Rubio-Briones, José, Seles, Maximilian, Mannweiler, Sebastian, Bosschieter, Judith, Kusuma, Venkata R.M., Ashabere, David, Huebner, Nicolai, Cotte, Juliette, Mertens, Laura S., Cohen, Daniel, Lunelli, Luca, Cussenot, Olivier, El Sheikh, Soha, Volanis, Dimitrios, Côté, Jean-François, Rouprêt, Morgan, Haitel, Andrea, Shariat, Shahrokh F., Mostafid, A. Hugh, Nieuwenhuijzen, Jakko A., Zigeuner, Richard, Dominguez-Escrig, Jose L., Hacek, Jaromir, Zlotta, Alexandre R., Burger, Maximilian, Evert, Matthias, Hulsbergen - van de Kaa, Christina A., van der Heijden, Antoine G., Kiemeney, Lambertus A.L.M., Soukup, Viktor, Molinaro, Luca, Gontero, Paolo, Llorente, Carlos, Algaba, Ferran, Palou, Joan, N’Dow, James, van der Kwast, Theo H., Babjuk, Marko, and Sylvester, Richard J.

Published
2021
Full Text
View/download PDF

32. Association Between Surgeon and Anesthesiologist Sex Discordance and Postoperative Outcomes: A Population-based Cohort Study

Author

Wallis, Christopher J. D., Jerath, Angela, Kaneshwaran, Kirusanthy, Hallet, Julie, Coburn, Natalie, Wright, Frances C., Conn, Lesley Gotlib, Bischof, Danielle, Covelli, Andrea, Klaassen, Zachary, Zlotta, Alexandre R., Kulkarni, Girish S., Luckenbaugh, Amy N., Armstrong, Kathleen, Lim, Kelvin, Bass, Barbara, Detsky, Allan S., and Satkunasivam, Raj

Published
2022
Full Text
View/download PDF

35. A multidisciplinary discussion of BladderPath

Author

St-Laurent, Marie-Pier, primary, Sfakianos, John P., additional, Rose, Tracy L., additional, Chung, Peter, additional, Kassouf, Wassim, additional, Zlotta, Alexandre R., additional, Inman, Brant, additional, and Black, Peter C., additional

Published
2023
Full Text
View/download PDF

41. Long‐term outcomes and cost savings of office fulguration of papillary Ta low‐grade bladder cancer.

Author

Vitug, Christian, Lajkosz, Katherine, Chavarriaga, Julian, Llano, Andres, Din, Shayan, Villegas, Eunice, Kuk, Cynthia, Chan, Amy, Gao, Bruce, Hemminki, Otto, Kot, Dhiral, Misurka, Jimmy, van der Kwast, Theodorus H., Wallis, Christopher, Jewett, Michael A. S., Soloway, Mark S., Fleshner, Neil E., Kulkarni, Girish S., and Zlotta, Alexandre R.

Subjects
BLADDER cancer, LOCAL anesthesia, INTRAVESICAL administration, TRANSURETHRAL resection of bladder, NON-muscle invasive bladder cancer, CANADIAN dollar
Abstract

Objectives: To assess whether office‐based fulguration (OF) under local anaesthesia for small, recurrent, pathological Ta low‐grade (LG) non‐muscle‐invasive bladder cancer (NMIBC) is an effective alternative to transurethral resection of bladder tumour (TURBT), avoiding the costs and risks of procedure, and anesthesia. Patients and Methods: Of 521 patients with primary TaLG NMIBC, this retrospective study included 270 patients who underwent OF during follow‐up for recurrent, small, papillary LG‐appearing tumours at a university centre (University Health Network, University of Toronto, Canada). We assessed the cumulative incidence of cancer‐specific mortality (CSM) and disease progression (to MIBC or metastases), as well as possible direct cost savings. Results: In the 270 patients with recurrent TaLG NMIBC treated with OF, the mean (sd) age was 64.9 (13.3) years, 70.8% were men, and 60.3% had single tumours. The mean (sd, range) number of OF procedures per patient was 3.1 (3.2, 1–22). The median (interquartile range) follow‐up was 10.1 (5.8–16.2) years. Patients also underwent a mean (sd) of 3.6 (3.0) TURBTs during follow‐up in case of numerous or bulkier recurrence. In all, 44.4% of patients never received intravesical therapy. The 10‐year incidence of CSM and progression were 0% and 3.1% (95% confidence interval 0.8–5.4%), respectively. Direct cost savings in Ontario were estimated at $6994.14 (Canadian dollars) per patient over the study follow‐up. Conclusions: This study supports that properly selected patients with recurrent, apparent TaLG NMIBC can be safely managed with OF under local anaesthesia with occasional TURBT for larger or numerous recurrent tumours, without compromising long‐term oncological outcomes. This approach could generate substantial cost‐saving to healthcare systems, is patient‐friendly, and could be adopted more widely. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

42. Data from Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial

Author

Fleshner, Neil E., primary, Sayyid, Rashid K., primary, Hansen, Aaron R., primary, Chin, Joseph L.K., primary, Fernandes, Ricardo, primary, Winquist, Eric, primary, van der Kwast, Theodorus, primary, Sweet, Joan, primary, Lajkosz, Katherine, primary, Kenk, Miran, primary, Hersey, Karen, primary, Veloso, Rosette, primary, Berlin, Doron, primary, Herrera-Caceres, Jaime O., primary, Sridhar, Srikala, primary, Moussa, Madeleine, primary, Finelli, Antonio, primary, Hamilton, Robert J., primary, Kulkarni, Girish S., primary, Zlotta, Alexandre R., primary, and Joshua, Anthony M., primary

Published
2023
Full Text
View/download PDF

43. Supplementary Tables 1-2 from Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial

Author

Fleshner, Neil E., primary, Sayyid, Rashid K., primary, Hansen, Aaron R., primary, Chin, Joseph L.K., primary, Fernandes, Ricardo, primary, Winquist, Eric, primary, van der Kwast, Theodorus, primary, Sweet, Joan, primary, Lajkosz, Katherine, primary, Kenk, Miran, primary, Hersey, Karen, primary, Veloso, Rosette, primary, Berlin, Doron, primary, Herrera-Caceres, Jaime O., primary, Sridhar, Srikala, primary, Moussa, Madeleine, primary, Finelli, Antonio, primary, Hamilton, Robert J., primary, Kulkarni, Girish S., primary, Zlotta, Alexandre R., primary, and Joshua, Anthony M., primary

Published
2023
Full Text
View/download PDF

44. Supplementary Material 1 from Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial

Author

Fleshner, Neil E., primary, Sayyid, Rashid K., primary, Hansen, Aaron R., primary, Chin, Joseph L.K., primary, Fernandes, Ricardo, primary, Winquist, Eric, primary, van der Kwast, Theodorus, primary, Sweet, Joan, primary, Lajkosz, Katherine, primary, Kenk, Miran, primary, Hersey, Karen, primary, Veloso, Rosette, primary, Berlin, Doron, primary, Herrera-Caceres, Jaime O., primary, Sridhar, Srikala, primary, Moussa, Madeleine, primary, Finelli, Antonio, primary, Hamilton, Robert J., primary, Kulkarni, Girish S., primary, Zlotta, Alexandre R., primary, and Joshua, Anthony M., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results